Background: The COVID-19 pandemic has profoundly impacted mental health, particularly exacerbating conditions such as depression, anxiety, insomnia, post-traumatic stress disorder (PTSD), and emotional disorders among hospitalized patients. This study examined the prevalence of COVID-19-related mental health issues and risk factors in hospitalized patients affiliated with MNUMS, compared to a control group. Aim: To assess the prevalence of mental health disorders such as depression, anxiety, insomnia, and post-traumatic stress disorder (PTSD), and to identify their associated risk factors. Materials and Methods: The study was conducted at hospitals under MNUMS, including the Mongolian-Japanese Hospital, Central Hospital, and the National Center for Maternal and Child Health. A total of 552 participants (399 case group, 153 control group) who were hospitalized were included. Depression (PHQ-9≥10), anxiety (GAD-7≥10), insomnia (ISI≥15), and PTSD (PCL-5≥33) were assessed using standardized scales. Analysis was performed using chi-square tests and binary logistic regression (crude odds ratio [cOR]/adjusted odds ratio [aOR], 95% confidence interval [CI]), adjusted for group, age, and sex. Results: In the case group, depression (23.1% vs. 13.7%, p=0.015, cOR=1.884 [1.124-3.156]), anxiety (16.8% vs. 11.1%, p=0.096), and any mental disorder (18.0% vs. 13.7%, p=0.225) were higher, while insomnia was lower (19.5% vs. 30.1%, p=0.008). PTSD was low overall (1.8% vs. 0.7%, p=0.333). Risk factors included female sex (p<0.001, cOR=0.362 for depression in males), younger age (p=0.004), unemployment (p=0.017), and prior trauma (p<0.001). COVID-19 symptoms (difficulty breathing) increased the risk of depression (p<0.001, cOR=2.828 [1.708-4.682]). Conclusion Hospitalization for COVID-19 increases the risk of depression and anxiety, modulated by demographic, clinical, and socioeconomic factors. Targeted interventions for vulnerable groups are essential.

Background: The COVID-19 pandemic has triggered a global mental health crisis. According to WHO estimates, anxiety and depression rose by 25% in the first year. In the post-COVID era, over 70% of patients experience depression, anxiety, insomnia, PTSD, and OCD, which can persist for up to 24 months. Hospitalized individuals face heightened risks due to infection severity, treatment stress, and social isolation. However, studies examining treatment outcomes and influencing factors remain limited. In Mongolia, mental health issues escalated sharply from 2020 to 2022; WHO data indicate that anxiety and stress were prevalent among healthcare workers and patients. Children and youth were particularly affected, with UNICEF studies emphasizing the urgent need for intervention. Suicide rates increased from 18.3 per 100,000. Long-term research on post-COVID mental disorders is scarce, impeding policy formulation. This study evaluates treatment outcomes in COVID patients and identifies key factors. By comparing case and control groups at 3 and 12 months, it uncovers differences in symptoms and treatment responses. The comparative design assesses statistical significance via P-values and subgroup success rates for CBT and SSRI therapies. Findings will enhance Mongolia’s mental health services. Larger-scale studies are essential moving forward. Objective: To evaluate treatment outcomes for post-COVID mental disorders and identify influencing factors. To analyze differences in psychological symptoms and treatment between case (COVID-19 positive) and control groups over 3 and 12 months. Material and Method: Retrospective comparative analysis of records from 281 patients (cases n=181, controls n=100) at a unified hospital from 2020-2022. At 12 months, n=200 (cases n=100, controls n=100). Patients were categorized by anxiety, depression, insomnia, and stress-related symptoms, with P-values calculated. Detailed subgroup analysis (n=47 treated patients) was conducted. Results: At 3 months, cases showed higher anxiety (56.4%, P=0.002), depression (41.4%, P<0.001), and insomnia (58%, P=0.107). At 12 months, differences lessened but anxiety (52%, P=0.023) and depression (35%, P=0.042) remained significant. COVID-related new symptoms were elevated in cases (e.g., depression 24.3%, P<0.001). Treatment subgroup success was 95.7% (P<0.001), with duration influencing outcomes (P=0.03). Conclusion Post-COVID mental symptoms persist long-term in cases, and extended treatment durations yield better results. Larger studies are required